Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.710 -0.090 (-1.55%)
Streaming Delayed Price Updated: 12:44 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $80 Million Proposed Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Shares Are Up Today: What's Going On? ↗
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its... 
Via Benzinga
News headline image
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high. 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations ↗
 
Via Benzinga
Topics Economy
News headline image
Candel Therapeutics Stock Surges Over 100% - Here's Why ↗
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency. 
Via Benzinga
News headline image
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug ↗
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years. 
Via Investor's Business Daily
News headline image
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024 ↗
Candel Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing ↗
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
News headline image
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments 
Via News Direct
News headline image
7 A-Rated Biotech Stocks Worth Betting on in June ↗
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
News headline image
Why BioRestorative Therapies Stock Is Moving Higher Thursday ↗
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic... 
Via Benzinga
News headline image
Candel Therapeutics to Join Russell 3000® Index
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
--News Direct-- 
Via News Direct
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
By Jeremy Golden, Benzinga 
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.